NSE BSE
dr. reddy s laboratories stock

DR. REDDY S LABORATORIES Share Price

- - (%)
- NSE: DRREDDY

DR. REDDY S LABORATORIES Share Price Update

As of the latest trading session, DR. REDDY S LABORATORIES share price is currently at 6750.1, which is up by 114.10 from its previous closing. Today, the stock has fluctuated between 6580.00 and 6780.00. Over the past year, DR. REDDY S LABORATORIES has achieved a return of 27.09 %. In the last month alone, the return has been 11.41 %. Read More...

DR. REDDY S LABORATORIES Performance

Day Range

Low6580.00 High6780.00
6636.00

52 Week Range

Low 5205.55 High 6884.95
6636.00

DR. REDDY S LABORATORIES Share Price

881

500124

DRREDDY

img img img img
No Data Available

Open Price

6580.00

Prev. Close

6636.00

Volume (Shares)

180068.00

Total traded value

11949.31

Upper Circuit

7299.60

Lower Circuit

5972.40

Note: The current prices & values are delayed, Login to your account for live updates.

DR. REDDY S LABORATORIES Fundamentals


(Standalone)

Market Cap (Cr) 112604.00
PE Ratio (TTM) 25.51
Book Value / Share 1458.96
Beta 0.43
ROE 19.42%
EPS (TTM) 256.80
Dividend Yield 0.60%
Net Profit Qtr (Cr) 1034.80

DR. REDDY S LABORATORIES Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 5081.80
Operating Expense 3978.30
Net Profit 1034.80
Net Profit Margin (%) 20.36
Earnings Per Share (EPS) 62.14
EBITDA 1591.30
Effective Tax Rate (%) 22.72
Particulars DEC 2023 (Values in Cr)
Revenue 4083.10
Operating Expense 3698.70
Net Profit 475.20
Net Profit Margin (%) 11.63
Earnings Per Share (EPS) 28.55
EBITDA 883.90
Effective Tax Rate (%) 24.79
Particulars SEP 2023 (Values in Cr)
Revenue 4819.10
Operating Expense 3461.20
Net Profit 1192.60
Net Profit Margin (%) 24.74
Earnings Per Share (EPS) 71.68
EBITDA 1852.19
Effective Tax Rate (%) 25.49
Particulars JUN 2023 (Values in Cr)
Revenue 5420.10
Operating Expense 3451.30
Net Profit 1639.40
Net Profit Margin (%) 30.24
Earnings Per Share (EPS) 98.66
EBITDA 2461.29
Effective Tax Rate (%) 26.13
Particulars MAR 2023 (Values in Cr)
Revenue 4537.80
Operating Expense 3732.20
Net Profit 672.40
Net Profit Margin (%) 14.81
Earnings Per Share (EPS) 40.49
EBITDA 1175.90
Effective Tax Rate (%) 28.20
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1699.87
ROE % 21.64
ROCE % 26.59
Total Debt to Total Equity 0.06
EBITDA Margin 31.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1405.34
ROE % 21.21
ROCE % 25.99
Total Debt to Total Equity 0.11
EBITDA Margin 30.16
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.21
ROE % 11.84
ROCE % 14.46
Total Debt to Total Equity 0.17
EBITDA Margin 20.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1072.02
ROE % 11.74
ROCE % 15.29
Total Debt to Total Equity 0.16
EBITDA Margin 22.10
Particulars MAR 2020 (Values in Cr)
Book Value / Share 944.61
ROE % 13.68
ROCE % 10.95
Total Debt to Total Equity 0.20
EBITDA Margin 17.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1459.23
ROE % 19.42
ROCE % 25.40
Total Debt to Total Equity 0.02
EBITDA Margin 34.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1236.56
ROE % 13.46
ROCE % 18.82
Total Debt to Total Equity 0.06
EBITDA Margin 28.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1111.56
ROE % 9.19
ROCE % 11.63
Total Debt to Total Equity 0.10
EBITDA Margin 21.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1032.48
ROE % 11.50
ROCE % 15.04
Total Debt to Total Equity 0.08
EBITDA Margin 25.97
Particulars MAR 2020 (Values in Cr)
Book Value / Share 920.13
ROE % 21.08
ROCE % 18.48
Total Debt to Total Equity 0.09
EBITDA Margin 30.49
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1727.70
Total Assets 38863.80
Total Liabilities 38863.80
Total Equity 28254.80
Share Outstanding 166818266
Price to Book Ratio 4.22
Return on Assets (%) 14.35
Return on Capital (%) 18.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1730.20
Total Assets 32285.10
Total Liabilities 32285.10
Total Equity 23286.10
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 13.96
Return on Capital (%) 18.47
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2419.20
Total Assets 29746.90
Total Liabilities 29746.90
Total Equity 19212.40
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 7.33
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2078.80
Total Assets 26616.80
Total Liabilities 26616.80
Total Equity 17641.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 7.33
Return on Capital (%) 9.6
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 205.30
Total Assets 23225.30
Total Liabilities 23225.30
Total Equity 15598.80
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 8.72
Return on Capital (%) 11.66
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1216.90
Total Assets 30359.30
Total Liabilities 30359.30
Total Equity 24240.80
Share Outstanding 166818466
Price to Book Ratio 4.22
Return on Assets (%) 14.30
Return on Capital (%) 17.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 645.80
Total Assets 25374.80
Total Liabilities 25374.80
Total Equity 20474.20
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 10.29
Return on Capital (%) 12.76
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2030.50
Total Assets 24495.60
Total Liabilities 24495.60
Total Equity 18336.20
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 6.62
Return on Capital (%) 7.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1646.50
Total Assets 21629.60
Total Liabilities 21629.60
Total Equity 16983.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 10.10
Return on Capital (%) 12.04
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.20
Total Assets 19475.80
Total Liabilities 19475.80
Total Equity 15191.90
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 15.08
Return on Capital (%) 18.07
Particulars MAR 2024 (Values in Cr)
Net Income 7201.00
Cash from Operations 6548.00
Cash from Investing -4028.30
Cash from Financing -376.30
Net change in Cash 138.70
Free Cash Flow 8188.30
Particulars MAR 2023 (Values in Cr)
Net Income 6048.50
Cash from Operations 6958.90
Cash from Investing -4137.30
Cash from Financing -2686.10
Net change in Cash -935.90
Free Cash Flow 8091.20
Particulars MAR 2022 (Values in Cr)
Net Income 3061.40
Cash from Operations 3554.50
Cash from Investing -2638.70
Cash from Financing -242.20
Net change in Cash -70.10
Free Cash Flow 5020.50
Particulars MAR 2021 (Values in Cr)
Net Income 2883.50
Cash from Operations 4141.90
Cash from Investing -2266.00
Cash from Financing -29.80
Net change in Cash 1274.50
Free Cash Flow 5116.00
Particulars MAR 2020 (Values in Cr)
Net Income 1885.70
Cash from Operations 3694.60
Cash from Investing -492.30
Cash from Financing -2515.90
Net change in Cash -24.10
Free Cash Flow 4179.20
Particulars MAR 2024 (Values in Cr)
Net Income 5791.30
Cash from Operations 4769.20
Cash from Investing -3430.30
Cash from Financing 68.10
Net change in Cash 87.50
Free Cash Flow 6130.29
Particulars MAR 2023 (Values in Cr)
Net Income 3866.00
Cash from Operations 5835.60
Cash from Investing -3447.60
Cash from Financing -2696.90
Net change in Cash -1091.60
Free Cash Flow 6835.80
Particulars MAR 2022 (Values in Cr)
Net Income 2223.80
Cash from Operations 1827.50
Cash from Investing -2038.00
Cash from Financing 505.50
Net change in Cash -193.80
Free Cash Flow 3138.80
Particulars MAR 2021 (Values in Cr)
Net Income 3056.20
Cash from Operations 3962.20
Cash from Investing -1458.00
Cash from Financing -794.30
Net change in Cash 1261.90
Free Cash Flow 4819.70
Particulars MAR 2020 (Values in Cr)
Net Income 2775.80
Cash from Operations 2316.10
Cash from Investing -1689.20
Cash from Financing -224.10
Net change in Cash -74.10
Free Cash Flow 2742.29
Company Name Price P/E P/B Market Cap 52 Week Low/High
DR. REDDY S LABORATORIES 6639.05 20.09 3.90 110759.07 5212.10 / 6882.70
BLISS GVS PHARMA LTD 110.15 12.05 1.19 1155.28 77.65 / 148.95
CIPLA LTD 1485.15 28.17 4.49 119928.54 1028.00 / 1581.70
FERMENTA BIOTECH LIMITED 229.35 0.00 2.33 675.00 137.10 / 262.00
GLAXOSMITHKLINE PHARMA LT 2570.70 66.32 24.49 43549.21 1376.50 / 2759.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
DR. REDDY S LABORATORIES 6639.05 25.85 4.55 110759.07 5212.10 / 6882.70
AMRUTAJAN HEALTH LTD 738.70 47.47 7.40 2135.63 556.05 / 826.00
ASTRAZENECA PHARMA IND LT 6349.65 106.48 22.29 15874.13 3730.00 / 7550.00
BLISS GVS PHARMA LTD 110.15 15.17 1.16 1155.28 77.65 / 148.95
ABBOTT INDIA LIMITED 27407.65 48.49 15.74 58241.26 21907.45 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 6660.20
  • 26 Days 6420.70
  • 10 Days 6628.80
  • 50 Days 6255.20
  • 12 Days 6601.30
  • 100 Days 6222.20
  • 20 Days 6469.90
  • 200 Days 5579.30
6655.58
PIVOT
First Resistance 6720.77
Second Resistance 6774.03
Third Resistance 6839.22
First Support 6602.32
Second Support 6537.13
Third Support 6483.87
RSI 66.90
MACD 180.59
Commodity Channel Index (CCI) 78.71
ADX 46.21
Williams % R -41.44

Over 1 Month

down

11.41

Over 3 Months

down

11.66

Over 6 Months

down

17.07

Over 1 Year

down

27.09

Over 3 Years

down

6.98

Over 5 Years

down

20.48

DR. REDDY S LABORATORIES Future

Future: Price

30 May
5880.00
27 Jun
5917.65
25 Jul
5919.30
25 May
0 100 200 300 400 500 600

Discount/Premium

25 Jul
-20.50
29 Aug
12.65
25 May
0 1 2 3 4 5 6 7

Active Calls

6000.0
4799
5900.0
2606
5950.0
1868
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

5900.0
655
5800.0
648
5700.0
411
25 Jul
0 500 1000 1500 2000 2500

DR. REDDY S LABORATORIES Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
35.62
Promoter Holdings
26.65
FII
27.67
DII
10.05
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
J P Morgan Chase Bank Na Public Shareholding 2.4343287E7 14.59
G V Prasad Shareholding of Promoter and Promoter Group 1.9219184E7 11.52
Satish Reddy Kallam Shareholding of Promoter and Promoter Group 1.6027126E7 9.61
Life Insurance Corporation Of India P & Gs Fund Public Shareholding 9210387.0 5.52
Kallam Satish Reddy Huf Shareholding of Promoter and Promoter Group 5523677.0 3.31
Nps Trust-a/c Sbi Pension Fund Scheme Tax Saver-tier 2 Public Shareholding 4220161.0 2.53
First Sentier Investors Icvc - Stewart Investors Asia Pacific Leaders Sustainability Fund Public Shareholding 3869125.0 2.32
Hdfc Trustee Company Ltd. A/c Hdfc Nifty 50 Etf Public Shareholding 2924821.0 1.75
Gunupati Venkateswara Prasad Huf Shareholding of Promoter and Promoter Group 2543418.0 1.52
Sbi Nifty Index Fund Public Shareholding 2147603.0 1.29
Icici Prudential Value Discovery Fund Public Shareholding 1949895.0 1.17
Mirae Asset Nifty India Manufacturing Etf Public Shareholding 1846278.0 1.11
Nippon Life India Trustee Ltd-a/c-nippon India Nifty 50 Value 20 Index Fund Public Shareholding 1709850.0 1.02
Samrajyam Reddy Kallam Shareholding of Promoter and Promoter Group 1120499.0 0.67
Anuradha Gunupati Shareholding of Promoter and Promoter Group 9205.0 0.01
Sharathchandra Reddy Gunupati Shareholding of Promoter and Promoter Group 2600.0 0.0
Vsd Holdings & Advisory Llp Shareholding of Promoter and Promoter Group 0.0 0.0
K Vishal Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
K Shravya Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
Gunupati Mallika Reddy Shareholding of Promoter and Promoter Group 5139.0 0.0
G Vani Sanjana Reddy Shareholding of Promoter and Promoter Group 5140.0 0.0
Deepti Reddy Kallam Shareholding of Promoter and Promoter Group 5140.0 0.0

DR. REDDY S LABORATORIES

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-07-11 40.0 Final 2023-07-12 Equity shares 2022-07-11 30.0 Final 2022-07-13 Equity shares 2021-07-09 25.0 Final 2021-07-13 Equity shares 2020-07-13 25.0 Final 2020-07-15 Equity shares 2019-07-15 20.0 Final 2019-07-17 Equity shares 2018-07-16 20.0 Final 2018-07-18 Equity shares 2017-07-17 20.0 Final 2017-07-19 Equity shares 2016-07-18 20.0 Final 2016-07-20 Equity shares 2015-07-10 20.0 Final 2015-07-14 Equity shares 2014-07-11 18.0 Final 2014-07-15 Equity shares 2013-07-12 15.0 Final 2013-07-16 Equity shares 2012-06-28 13.75 Final 2012-07-03 Equity shares 2011-06-30 11.25 Final 2011-07-05 Equity shares 2010-07-02 11.25 Final 2010-07-06 Equity shares 2009-07-03 6.25 Final 2009-07-07 Equity shares 2008-07-04 3.75 Final 2008-07-08 Equity shares 2007-07-06 3.75 Final 2007-07-10 Equity shares 2006-07-07 0.0 Final 2006-07-11 Equity shares 2005-07-07 0.0 Final 2005-07-11 Equity shares
Ex-Date Ex-Bonus Ratio
2006-08-29 2006-08-28 1:1 1994-05-03 1994-04-08 2:1
Ex-Date Old FV NEW FV Record Date
2001-10-10 10.0 5.0 2001-10-25

Dr Reddy's Laboratories Limited Overview

Dr. Reddy's Laboratories Ltd, an eminent pharmaceutical company based in India, offers an extensive portfolio across Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Dominating its revenue, the Global Generics Segment, constituting about 83% in FY22, includes over 400 generic drugs with significant contributions from nervous system, gastrointestinal, and anti-infective drugs. The Pharmaceutical Services & Active Ingredients (PSAI) segment, accounting for 14% of revenues, underscores its position as one of the world's largest API manufacturers, benefiting its generics business with cost competitiveness. Meanwhile, its proprietary products focus on differentiated formulations, with subsidiary Aurgene Discovery advancing novel therapeutics for cancer and inflammation. Geographically, the USA leads its revenue share at 37%, followed by India and Russia. The company boasts 23 manufacturing facilities worldwide and maintains a strategic focus on niche products, injectables, and biosimilars to enhance profitability. FY21 saw partnerships for COVID-19 treatments, including the launch of the Sputnik-V vaccine in India. Recent divestments and acquisitions, such as the portfolio from Eton Pharmaceuticals, reflect its commitment to streamlining operations and expanding its product offerings, supporting its mission to provide affordable medications globally.

Learn More About Stocks

About DR. REDDY S LABORATORIES

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by DR. REDDY S LABORATORIES

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Dr Reddys Laboratories Ltd?

Answer Field

The share price of Dr Reddys Laboratories Ltd for NSE is ₹ 6750.1 and for BSE is ₹ 6721.35.

What is the Market Cap of Dr Reddys Laboratories Ltd?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE is ₹ 11,26,04.00 Cr. and for BSE is ₹ 11,21,24.40 Cr. as of now.

What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

Answer Field

The 52 Week High and Low of Dr Reddys Laboratories Ltd for NSE is ₹ 6884.95 and ₹ 5205.55 and for BSE is ₹ 6882.70 and ₹ 5212.10.

How to Buy Dr Reddys Laboratories Ltd share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Dr Reddys Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 27.09%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7.5 Lacs+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300 Cr MTF Book

icon-with-text
loader